

or physiologically acceptable salts thereof, wherein:

ring A is substituted or unsubstituted;

Q is -N= or -CR<sup>2</sup>=;

X is S, O, or NOR<sup>3</sup>;

Y is -S-, -SO- or -SO<sub>2</sub>-;

R<sup>2</sup> is -H or a substituent;


R<sup>3</sup> is -H or -C(O)R<sup>4</sup>;

R<sup>4</sup> is a substituted or unsubstituted aliphatic or aromatic group;

n is 0 or 1; and wherein:


when X is S or NOR<sup>3</sup>, R is a substituted or unsubstituted aromatic or aralkyl group and R<sup>1</sup> is hydrogen or a substituted or unsubstituted aliphatic group;

when X is O and n is 0, R<sup>1</sup> is hydrogen or a substituted or unsubstituted aliphatic group and R is a substituted or unsubstituted aromatic or aralkyl group, provided that R is not 2-thienyl, benzoxadiazolyl, 4-oxo-4H-1-benzopyran-3-yl, 6-chloro-4-oxo-4H-1-benzopyran-3-yl, 6-methyl-4-oxo-4H-1-benzopyran-3-yl, 6-acetyloxy-4-oxo-4H-1-benzopyran-3-yl, naphthyl, 3-furanyl, 2-furanyl, 2-pyridyl, 3-pyridinyl, 4-pyridyl, 2,4-dichlorophenyl, 2,6-dichlorophenyl, 4-acetyloxy-3-methoxyphenyl, 3,5-dimethoxyphenyl, 3,4,5-trimethoxyphenyl, 3,5-*t*-butyl-4-hydroxyphenyl, 3,5-*i*-propyl-4-hydroxyphenyl, 3-(2-hydroxyphenyl)-1H-pyrazol-4-yl, 3-(5-chloro-2-hydroxyphenyl)-1H-pyrazol-4-yl, or



where R<sup>14</sup> is H, *p*-F, *o*-Cl, *p*-Cl, *p*-Br, *m*-Br, *o*-CH<sub>3</sub>, *p*-CH<sub>3</sub>, *p*-OCH<sub>2</sub>CH<sub>3</sub>, -O-Benzyl, CF<sub>3</sub>, phenyl, -OCH<sub>3</sub>, -O-phenyl, NO<sub>2</sub>, -OC(O)CH<sub>3</sub>, -OCH<sub>2</sub>C(O)C<sub>2</sub>H<sub>5</sub>, -OCH<sub>2</sub>C(O)NHNH<sub>2</sub>, *p*-(-O-(CH<sub>2</sub>)<sub>5</sub>-N(CH<sub>3</sub>)<sub>2</sub>), *p*-(-O-(CH<sub>2</sub>)<sub>3</sub>-N(C<sub>3</sub>H<sub>7</sub>)<sub>2</sub>), *p*-(3-piperidin-1-yl-propan-1-oxy), *m*-(2-morpholin-4-yl-ethan-1-oxy), or *m*-(4-(4-ethyl-piperazin-1-yl)-butan-1-oxy); and

when X is O and n is 1, R<sup>1</sup> is H or a substituted or unsubstituted aliphatic group and R is a substituted or unsubstituted aromatic or aralkyl group, provided that R is not 4-nitro-2-methoxyphenyl, 4-methoxy-2-nitrophenyl, 4-chloro-2-nitrophenyl, 2,5-dichlorophenyl, or



where R<sup>15</sup> is H, Cl, *p*-NO<sub>2</sub>, *o*-NO<sub>2</sub>, *p*-OCH<sub>3</sub>, *o*-CO<sub>2</sub>H, CH<sub>3</sub> or CF<sub>3</sub>.

a<sup>2</sup>  
B<sup>1</sup>

20. A compound of Claim 18, wherein Q is CH<sub>2</sub>; Y is S; and R is selected from the group consisting of substituted or unsubstituted pyrrole, pyrazole, imidazole, oxazole, isoxazole, thiazole, isothiazole, triazole, tetrazole, indole, 7-azaindole, indazole, purine, pyrrolo-pyrimidine, pyrazolo-pyrimidine, imidazo-pyridine, imidazo-pyrimidine, imidazo-pyridine, pyrrolo-pyridine, pyrrolo-pyridine, pyrrolo-quinoline, pyrrolo-pyrazine, 6,7,8,9-tetrahydropyrido-indole and tetrahydrofuran.

Please add new claims 37 and 38 as follows:

a<sup>3</sup>

--37. The compound which is 2-(1-(4-acetoxybutyl)-7-azaindol-3-yl)methylene-2H-1,4-benzothiazin-3(4H)-one, or a physiologically acceptable salt thereof.

38. A pharmaceutical composition comprising the compound of claim 37, or a physiological salt thereof, and a pharmaceutically acceptable diluent or carrier.--